328 related articles for article (PubMed ID: 36574172)
1. Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder.
Venier LM; Clerici B; Bissola AL; Modi D; Jevtic SD; Radford M; Mahamad S; Nazy I; Arnold DM
Int J Hematol; 2023 Mar; 117(3):341-348. PubMed ID: 36574172
[TBL] [Abstract][Full Text] [Related]
2. [Heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia: novel insights on anti-platelet factor 4 antibodies].
Atsushi Y
Rinsho Ketsueki; 2022; 63(9):1233-1241. PubMed ID: 36198549
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond.
Greinacher A; Warkentin TE
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):1-10. PubMed ID: 38066843
[TBL] [Abstract][Full Text] [Related]
4. Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT.
Warkentin TE; Arnold DM; Sheppard JI; Moore JC; Kelton JG; Nazy I
J Thromb Haemost; 2023 Aug; 21(8):2268-2276. PubMed ID: 37182698
[TBL] [Abstract][Full Text] [Related]
5. Laboratory Testing for Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: A Narrative Review.
Warkentin TE; Greinacher A
Semin Thromb Hemost; 2023 Sep; 49(6):621-633. PubMed ID: 36455619
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia.
Huynh A; Arnold DM; Ivetic N; Clare R; Hadzi-Tosev M; Liu Y; Smith JW; Bissola AL; Daka M; Kelton JG; Nazy I
J Thromb Haemost; 2023 Oct; 21(10):2833-2843. PubMed ID: 37394121
[TBL] [Abstract][Full Text] [Related]
7. [Novel disease entities due to antiplatelet factor 4 antibodies: HIT, aHIT, and VITT].
Yasumoto A
Rinsho Ketsueki; 2022; 63(5):454-462. PubMed ID: 35662171
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating anti-PF4 disorders: An overview.
Warkentin TE
Semin Hematol; 2022 Apr; 59(2):59-71. PubMed ID: 35512902
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia.
Warkentin TE; Greinacher A
Thromb Res; 2021 Aug; 204():40-51. PubMed ID: 34144250
[TBL] [Abstract][Full Text] [Related]
10. Serotonin Release Assay: Functional Assay for Heparin- and Vaccine-Induced (Immune) Thrombotic Thrombocytopenia.
Kondo M; Donikian D; Brighton TA
Methods Mol Biol; 2023; 2663():463-477. PubMed ID: 37204730
[TBL] [Abstract][Full Text] [Related]
11. Potential mechanisms of vaccine-induced thrombosis.
Marietta M; Coluccio V; Luppi M
Eur J Intern Med; 2022 Nov; 105():1-7. PubMed ID: 35953336
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.
McGonagle D; De Marco G; Bridgewood C
J Autoimmun; 2021 Jul; 121():102662. PubMed ID: 34051613
[TBL] [Abstract][Full Text] [Related]
13. Uncommon thrombotic complications after SARS-CoV-2 vaccination.
Musil D
Vnitr Lek; 2021; 67(5):297-302. PubMed ID: 35459396
[TBL] [Abstract][Full Text] [Related]
14. Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies.
Kanack AJ; Jones CG; Singh B; Leger RR; Splinter NP; Heikal NM; Pruthi RK; Chen D; George G; Abou-Ismail MY; Wool GD; Gundabolu K; Padmanabhan A
Blood; 2022 Dec; 140(25):2722-2729. PubMed ID: 35998675
[TBL] [Abstract][Full Text] [Related]
15. Laboratory testing for VITT antibodies.
Warkentin TE; Greinacher A
Semin Hematol; 2022 Apr; 59(2):80-88. PubMed ID: 35512905
[TBL] [Abstract][Full Text] [Related]
16. Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT).
Gabarin N; Arnold DM; Nazy I; Warkentin TE
Semin Hematol; 2022 Apr; 59(2):89-96. PubMed ID: 35512906
[TBL] [Abstract][Full Text] [Related]
17. Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies.
Schönborn L; Thiele T; Esefeld M; El Debuch K; Wesche J; Seck SE; Kaderali L; Wolff M; Warkentin TE; Greinacher A
J Thromb Haemost; 2022 Nov; 20(11):2579-2586. PubMed ID: 36006172
[TBL] [Abstract][Full Text] [Related]
18. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide.
Reilly-Stitt C; Jennings I; Kitchen S; Makris M; Meijer P; de Maat M; Scully M; Bakchoul T; Walker ID
J Thromb Haemost; 2022 Aug; 20(8):1875-1879. PubMed ID: 35603519
[TBL] [Abstract][Full Text] [Related]
19. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021.
Reilly-Stitt C; Kitchen S; Jennings I; Horner K; Jones R; Makris M; Walker ID
J Thromb Haemost; 2021 Sep; 19(9):2263-2267. PubMed ID: 34227230
[TBL] [Abstract][Full Text] [Related]
20. Heparin-Induced Thrombotic Thrombocytopenia (HITT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Similar but Different.
Favaloro EJ; Pasalic L
Methods Mol Biol; 2023; 2663():405-415. PubMed ID: 37204726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
